Candel Therapeutics Targets 2025 BLA Submission for Prostate Cancer Treatment

Key Facts

Amid a shifting landscape in oncology development, Candel Therapeutics has outlined a definitive regulatory path for its lead clinical program. The company aims to submit a biologics license application (BLA) for its localized prostate cancer treatment to the FDA by the end of 2025. This strategic milestone was highlighted during a presentation at the Cantor Fitzgerald Global Healthcare Conference, focusing on late-stage data from its viral immunotherapy pipeline.

Per market data, shares of CADL closed at $11.33 on September 10, 2026, having fluctuated between a day low of $11.2 and a high of $12.05 during that session. This price action follows the company's efforts to provide increased visibility into its clinical milestones and regulatory goals, as presented by leadership to industry stakeholders and investors.

Investors should watch for price consolidation around the $11.33 level (as of close September 10, 2026) as the market digests the 2025 submission timeline. While the upcoming economic calendar shows no immediate sector-specific catalysts, the stock's performance will likely remain sensitive to further clinical data readouts and FDA feedback regarding the BLA process.